Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739730 | 0.86 | PTPN2 (0.46) | POLBPKMMAPTMEN1KMT2A | |
| SCHEMBL10109854 | 0.86 | PTPN2 (0.49) | POLBPKMMAPTMEN1KMT2A | |
| SCHEMBL7042355 | 0.83 | GSK3B (0.50) | POLBPKMMAPTMEN1KMT2A | |
| SCHEMBL1529974 | 0.79 | GSK3B (0.53) | POLBPKMMAPTMEN1KMT2A | |
| SCHEMBL20912901 | 0.78 | CYP4F2 (0.46) | POLBPKMMAPTMEN1KMT2A | |
| SCHEMBL3878737 | 0.78 | USP10 (0.56) | POLBPKMMAPTKMT2ALMNA | |
| SCHEMBL2241077 | 0.77 | TSHR (0.52) | MAPTMEN1KMT2APTPN2HDAC3 | |
| SCHEMBL20481990 | 0.77 | PTPN2 (0.47) | POLBPKMMAPTMEN1KMT2A | |
| SCHEMBL6812309 | 0.76 | PTPN2 (0.49) | POLBPKMMAPTMEN1KMT2A | |
| SCHEMBL6286251 | 0.76 | TDP1 (0.51) | POLBPKMMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240170735-A1 | FLAME RETARDANTS FOR BATTERY ELECTROLYTES | ALBEMARLE CORPORATION | 2024-05-23 | — | — | US | claimed |
| EP-4315472-A1 | FLAME RETARDANTS FOR BATTERY ELECTROLYTES | ALBEMARLE CORPORATION (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2022212634-A1 | FLAME RETARDANTS FOR BATTERY ELECTROLYTES | ALBEMARLE CORPORATION (US) | 2022-10-06 | — | — | WO | claimed |
| US-20240170735-A1 | FLAME RETARDANTS FOR BATTERY ELECTROLYTES | ALBEMARLE CORPORATION | 2024-05-23 | — | — | US | disclosed |
| EP-4315472-A1 | FLAME RETARDANTS FOR BATTERY ELECTROLYTES | ALBEMARLE CORPORATION (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157792-A | Flame retardant for battery electrolyte | 雅宝公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2022212634-A1 | FLAME RETARDANTS FOR BATTERY ELECTROLYTES | ALBEMARLE CORPORATION (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2019169479-A1 | DIPHENYL SUBSTITUTED THIOPHENE-2-AMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS ANTIMICROBIAL | DENOVAMED INC. (CA) | 2019-09-12 | — | — | WO | disclosed |
| US-9975910-B2 | Hetero-fused cyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20160168176-A1 | HETERO-FUSED CYCLIC COMPOUND | Eisai R&D Management Co., Lt.d (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3026054-A1 | HETERO-CONDENSED RING COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2016-06-01 | — | — | EP | disclosed |
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2376482-B1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2013-03-06 | — | — | EP | disclosed |
| WO-2012116452-A1 | ANTIMICROBIAL/ADJUVANT COMPOUNDS AND METHODS | DENOVAMED INC. (CA) | 2012-09-07 | — | — | WO | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2010075962-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
| US-20100076028-A1 | Design and Synthesis of Novel Antimicrobials | WU FAN | 2010-03-25 | — | — | US | disclosed |
| WO-2006092059-A1 | DESIGN AND SYNTHESIS OF NOVEL ANTIMICROBIALS | WU FAN (CA) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076028-A1 | Design and Synthesis of Novel Antimicrobials | MLX, LPXN, TPX2 | POLB 1277/4885PKM 2814/4885MAPT 4883/4885 |
| US-20160168176-A1 | HETERO-FUSED CYCLIC COMPOUND | NR3C2, NR1H4, NR1I3 | POLB 2899/4885PKM 3913/4885MAPT 4653/4885 |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | TPMT, MAVS, EIF2AK2 | POLB 1390/4885PKM 726/4885MAPT 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.